108 related articles for article (PubMed ID: 23086186)
1. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment.
Habibi MS; Openshaw PJ
Curr Opin Infect Dis; 2012 Dec; 25(6):687-94. PubMed ID: 23086186
[TBL] [Abstract][Full Text] [Related]
2. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
Shafique M; Wilschut J; de Haan A
Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
[TBL] [Abstract][Full Text] [Related]
3. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.
Johnson TR
Expert Rev Vaccines; 2006 Jun; 5(3):371-80. PubMed ID: 16827621
[TBL] [Abstract][Full Text] [Related]
5. Immune responses and disease enhancement during respiratory syncytial virus infection.
Openshaw PJ; Tregoning JS
Clin Microbiol Rev; 2005 Jul; 18(3):541-55. PubMed ID: 16020689
[TBL] [Abstract][Full Text] [Related]
6. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
7. Host response to respiratory syncytial virus infection.
Arruvito L; Raiden S; Geffner J
Curr Opin Infect Dis; 2015 Jun; 28(3):259-66. PubMed ID: 25887611
[TBL] [Abstract][Full Text] [Related]
8. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.
Garg R; Shrivastava P; van Drunen Littel-van den Hurk S
Expert Rev Vaccines; 2012 Dec; 11(12):1441-57. PubMed ID: 23252388
[TBL] [Abstract][Full Text] [Related]
9. Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection.
Piedimonte G
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S66-74; discussion S74-5. PubMed ID: 12671455
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen.
Park JW; Taube C; Yang ES; Joetham A; Balhorn A; Takeda K; Miyahara N; Dakhama A; Donaldson DD; Gelfand EW
J Allergy Clin Immunol; 2003 Dec; 112(6):1078-87. PubMed ID: 14657862
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus infection in adults.
Falsey AR
Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771
[TBL] [Abstract][Full Text] [Related]
13. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
14. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus.
Larrañaga CL; Ampuero SL; Luchsinger VF; Carrión FA; Aguilar NV; Morales PR; Palomino MA; Tapia LF; Avendaño LF
Pediatr Infect Dis J; 2009 Oct; 28(10):867-73. PubMed ID: 19738511
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus and other respiratory viruses.
Welliver RC
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S6-10; discussion S10-2. PubMed ID: 12671447
[TBL] [Abstract][Full Text] [Related]
16. CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness.
Schwarze J; Cieslewicz G; Joetham A; Ikemura T; Hamelmann E; Gelfand EW
J Immunol; 1999 Apr; 162(7):4207-11. PubMed ID: 10201948
[TBL] [Abstract][Full Text] [Related]
17. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
[TBL] [Abstract][Full Text] [Related]
18. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
Voges B; Vallbracht S; Zimmer G; Bossow S; Neubert WJ; Richter K; Hobeika E; Herrler G; Ehl S
Cell Immunol; 2007 Jun; 247(2):85-94. PubMed ID: 17904538
[TBL] [Abstract][Full Text] [Related]
20. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection.
de Waal L; Koopman LP; van Benten IJ; Brandenburg AH; Mulder PG; de Swart RL; Fokkens WJ; Neijens HJ; Osterhaus AD
J Med Virol; 2003 Jun; 70(2):309-18. PubMed ID: 12696123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
